– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor –
– Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury –
LOS ALTOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that several presentations were delivered on the Company's two product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress. OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator initially targeting acute kidney injury (AKI).
— 高磷血癥臨床前模型的結果表明 OLC 與 Tenapanor 相比的相對效力 —
— 口服 UNI-494 在臨床前模型中顯示出有望作爲預防與急性腎損傷相關的延遲移植物功能的潛在候選藥物 —
加利福尼亞州洛斯阿爾託斯,2024年5月28日(GLOBE NEWSWIRE)——爲腎臟疾病患者開發療法的臨床階段生物技術公司Unicycive Therapeutics, Inc.(納斯達克股票代碼:UNCY)(“公司” 或 “Unicycive”)今天宣佈,在第61屆歐洲會議上就該公司的兩種候選產品碳酸乙酯(OLC)和 UNI-494 發表了幾場演講腎臟協會(ERA)大會。OLC 是新一代的鋰基磷酸鹽結合劑,採用正在開發的專有納米顆粒技術,用於治療慢性腎臟病 (CKD) 患者的高磷血癥。UNI-494 是一種新型煙酰胺酯衍生物,是一種選擇性的 ATP 敏感線粒體鉀通道激活劑,最初針對急性腎損傷 (AKI)。